Abstract

BackgroundHistone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV. The inhibitors selectively targeting individual HDAC have been proved to be the better candidate antitumor drugs. To screen selective HDAC inhibitors, several proteochemometric (PCM) models based on different combinations of three kinds of protein descriptors, two kinds of ligand descriptors and multiplication cross-terms were constructed in our study.ResultsThe results show that structure similarity descriptors are better than sequence similarity descriptors and geometry descriptors in the leftacterization of HDACs. Furthermore, the predictive ability was not improved by introducing the cross-terms in our models. Finally, a best PCM model based on protein structure similarity descriptors and 32-dimensional general descriptors was derived (R2 = 0.9897, Qtest2 = 0.7542), which shows a powerful ability to screen selective HDAC inhibitors.ConclusionsOur best model not only predict the activities of inhibitors for each HDAC isoform, but also screen and distinguish class-selective inhibitors and even more isoform-selective inhibitors, thus it provides a potential way to discover or design novel candidate antitumor drugs with reduced side effect.

Highlights

  • Histone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV

  • Proteochemometric modeling In our study, 18 proteochemometric models were created from training set with combinations of different descriptors

  • The model derived based on P1 and General Descriptor (GD) showed to be the best model with the highest predictive ability (Qc2v = 0.7162 and Qt2est = 0.7542)

Read more

Summary

Introduction

Histone deacetylase (HDAC) is a novel target for the treatment of cancer and it can be classified into three classes, i.e., classes I, II, and IV. The inhibitors selectively targeting individual HDAC have been proved to be the better candidate antitumor drugs. Only proteins with widespread biological significance for the tumor cells growth regulation are most possible to be the targets of broad-spectrum lowtoxic antitumor drugs. Histone deacetylases (HDACs) are proved to be novel epigenetic targets for the treatment of cancer [1,2,3]. Histone deacetylase inhibitors (HDACi) have extensively demonstrated the antitumor efficacy in vitro and in vivo. The related study of HDACi has become one of the most important research fields of the antitumor drugs, especially during the coming area of epigenetics

Objectives
Methods
Results
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.